DNL.L Share News (DNL)

TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

TRADING UPDATES: Trackwise Designs wins deal; Cake Box names CFO

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

Diurnal treatment gets approval from Welsh regulatory body

(Alliance News) - Diurnal Group PLC on Friday said its Efmody treatment has been recommended as an option to treat patients with congenital adrenal hyperplasia.

Diurnal's 'Efmody' treatment gets thumbs-up for NHS Wales

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommended its 'Efmody' hydrocortisone modified-release hard capsules as an option for restricted use to treat adolescents and adults with congenital adrenal hyperplasia (CAH) within NHS Wales.

Diurnal annual loss widens despite revenue growth as costs balloon

(Alliance News) - Diurnal Group PLC on Wednesday reported a widened annual loss as costs, especially on research & development, surged.

UK earnings, trading statements calendar - next 7 days

LONDON MARKET CLOSE: Stocks move into reverse as pessimism takes over

(Alliance News) - Stocks in London returned from the long weekend on Tuesday to close in the red despite spending most of the session in the green, as investors wiped out the morning's gains following selling pressure in the US.

Diurnal to be taken over by Neurocrine Biosciences for £48.3m, shares surge

(Sharecast News) - Diurnal shares surged on Tuesday after it agreed to be taken over by US biotech firm Neurocrine Biosciences for £48.3m.

Diurnal shares double on GBP48 million takeover from Neurocrine

(Alliance News) - Diurnal Group PLC on Tuesday said it agreed to a GBP48.3 million takeover from US biopharmaceutical firm Neurocrine Biosciences Inc.

AIM WINNERS & LOSERS: Diurnal shares more than double on takeover bid

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

IN BRIEF: Diurnal more than doubles product sales in 2022

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says product sales in the year ended June 30, more than doubled to GBP4.6 million from GBP2.3 million the previous year. Revenue in the year totals GBP4.7 million including licensing income of GBP600,000, up from GBP4.4 million the previous year, including licensing income of GBP2.1 million.

TRADING UPDATES: Indivior, Diurnal start trials; Alien Metals tests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Director dealings: K3 director linked to purchase, Diurnal exec sells shares into ISA

(Sharecast News) - Software company K3 Business Technology was at the top of the list of buys on Monday, after Kestrel Partners spent more than £40k on its shares.

IN BRIEF: Diurnal expands distribution agreement with EffRx

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Extends distribution and marketing agreement with EffRx Pharmaceuticals in Switzerland to include Efmody.